RAPP
Rapport Therapeutics, Inc. Common Stock
RAPP
Rapport Therapeutics, Inc. Common Stock
RAPP
Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
Rapport Therapeutics is differentiated by RAP-219's neuroanatomically selective pharmacology and a 22-day half-life, supporting a bullish outlook. RAPP is fully funded through pivotal Phase 3 trials,